Every material Form 8-K Acadia Pharmaceuticals filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Acadia Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher on December 11, 2024, after the Hart-Scott-Rodino waiting period expired. The company received $150.0 million at closing, and one third of the net proceeds are payable to Neuren Pharmaceuticals under a 2023 joint venture and license agreement, so shareholders will receive less than the full amount.
Sale closed December 11, 2024, after the Hart-Scott-Rodino waiting period expired.
Company received $150.0 million at closing under the PRV Transfer Agreement dated November 5, 2024.
One third of the net proceeds from the voucher sale are payable to Neuren Pharmaceuticals Limited under a July 13, 2023 agreement.
The voucher was received in March 2023 with FDA approval of DAYBUE (trofinetide) for Rett syndrome.
Acadia Pharmaceuticals said Executive Vice President, Chief Operating Officer and Head of Commercial Brendan Teehan was involuntarily terminated without Cause, effective immediately. Mr. Teehan will stay on as a non-executive employee through December 31, 2024 to help transfer his duties to a successor, and CEO Catherine Owen Adams will assume his responsibilities until one is appointed.
Brendan Teehan's executive role ended effective immediately, per an agreement dated November 18, 2024
Teehan remains a non-executive employee until December 31, 2024 to assist with the transition
CEO Catherine Owen Adams will assume his responsibilities until a successor is appointed
The filing does not name a successor or state the reason for the termination
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Acadia Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →